Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma

Yang, Peiyu; Xu, Weiling; Liang, Xinyue; Yu, Shanshan; Yi, Xingcheng; Liu, Mengmeng; Tian, Mengru; Yue, Taohua; Zhang, Yingjie; Yan, Yurong; Hu, Zhongli; Guo, Qiang; Zhang, Nan; Wang, Jingxuan; Sun, Xiaoli; Hu, Rui; Kumar, Shaji; Dai, Yun; Jin, Fengyan

doi:10.1002/ajh.26810

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that patients with a pattern of MRD that was stable or increasing over time had a signi cantly worse PFS than patients with a pattern of MRD that was decreasing. This nding is consistent with the results of a study by Paiva et al, which found that patients with a pattern of MRD that was stable or increasing over time had a signi cantly shorter OS than patients with a pattern of MRD that was decreasing (11).…”

Section: Discussionsupporting

confidence: 92%

Measurable Residual Disease (MRD) dynamics in Multiple Myeloma and the influence of Clonal Diversity Analyzed by Artificial Intelligence

Martínez-López,

Lopez-Muñoz,

Chari

et al. 2024

Preprint

View full text Add to dashboard Cite

Minimal Residual Disease (MRD) assessment is a known surrogate marker for survival in multiple myeloma (MM). Here, we present a single institution’s experience assessing MRD by NGS of Ig genes and the long-term impact of depth of response as well as clonal diversity on the clinical outcome of a large population of MM patients; 482 MM patients at the University of California, San Francisco (UCSF) diagnosed from 2008 to 2020 were analyzed retrospectively. MRD assessment was performed by NGS. PFS curves were plotted by the Kaplan-Meier method. In the newly diagnosed group, 119 of 304, achieved MRD negativity at the level of 10− 6 at least once. These patients had a prolonged PFS versus patients who were persistently MRD positive at different levels (p > 0.0001). In the relapsed disease group, 64 of 178 achieved MRD negativity at 10− 6 and PFS was prolonged versus patients who remained MRD positive (p = 0.03). Three categories of MRD dynamics were defined by artificial intelligence: (A) patients with ≥ 3 consistently MRD negative samples, (B) patients with continuously declining but detectable clones, (C) patients with either increasing or a stable number of clones. Groups A and B had a more prolonged PFS than group C (p < 10− 7). Patients who were MRD positive and had not yet relapsed had a higher clonal diversity than those patients who were MRD positive and had relapsed. MRD dynamics can accurately predict disease evolution and drive clinical decision-making. Clonal Diversity could complement MRD assessment in the prediction of outcomes in MM.

show abstract

Section: Discussionsupporting

confidence: 92%

Measurable Residual Disease (MRD) dynamics in Multiple Myeloma and the influence of Clonal Diversity Analyzed by Artificial Intelligence

Martínez-López,

Lopez-Muñoz,

Chari

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, sustaining MRD negativity for over one year was identified as a benchmark indicative of long-term survival and, in certain instances, potential cure. Yang et al [ 8 ] observed that patients who sustained negative MRD for over 12 months experienced notably prolonged PFS and OS. This supports the notion that the duration of maintaining negative MRD can function as a dependable prognostic indicator.…”

Section: Application Of Mrd In the Treatment For MMmentioning

confidence: 99%

“…Importantly, their survival duration was notably higher compared to patients who tested positive for MRD. Yang et al [ 8 ] conducted research on MRD and noted a lack of synchronization between the MRD status and conventional efficacy assessments, such as CR, particularly concerning the timing of these assessments. The prognostic significance of being MRD-negative is essentially equivalent to that of sCR.…”

Section: Application Of Mrd In the Treatment For MMmentioning

confidence: 99%

“…A study by Yang et al [ 8 ] revealed that during the treatment process, the status of MRD and sFLCR may not be synchronized. Approximately 24% of patients exhibited negativity in both MRD and normal sFLCR concurrently, around 18% had MRD negativity before or after the normalization of sFLCR, and roughly 30% of patients with MRD-negative status had abnormal sFLCR.…”

Section: Correlation Between Mrd and Sflcr In The Treatment Of MMmentioning

confidence: 99%

See 1 more Smart Citation

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

Zhu,

Hu,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.

show abstract

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

Xu,

Liang,

Liu

et al. 2024

Clinical Medicine

View full text Add to dashboard Cite

Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma

Cited by 4 publications

References 8 publications

Measurable Residual Disease (MRD) dynamics in Multiple Myeloma and the influence of Clonal Diversity Analyzed by Artificial Intelligence

Measurable Residual Disease (MRD) dynamics in Multiple Myeloma and the influence of Clonal Diversity Analyzed by Artificial Intelligence

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

Contact Info

Product

Resources

About